Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00059449
Status:
COMPLETED
Last Update Posted:
2010-01-13
First Post:
2003-04-25
Brief Title:
Role of Epidermal Growth Factor EGF in Development of Necrotizing Enterocolitis
Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Organization:
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Study Overview
Official Title:
Role of Epidermal Growth Factor EGF in Development of Necrotizing Enterocolitis
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Necrotizing enterocolitis NEC is a serious gastrointestinal disorder that primarily affects preterm infants About 10 of babies less than 32 weeks gestation at birth will develop it Overall 30 of babies who develop NEC will die from it with many others developing long term gastrointestinal problems The most important factor in its development is a premature intestinal tract Epidermal growth factor EGF is an important growth factor in the development and maintenance of the gastrointestinal tract This study will look for a relationship between EGF levels in premature babies and the development of NEC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: